{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:22:10Z","timestamp":1787757730076,"version":"build-2784847793"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The use of tumor necrosis factor-\u03b1 inhibitors (TNFi) has been associated with an increased risk latent tuberculosis (TB) reactivation. The role of TB screening assays in monitoring patients during TNFi therapy remains uncertain. Spontaneous conversions and reversions have been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aims to determine the conversion and reversion rate of TB screening tests among dermatology patients receiving TNFi in a country with moderate TB incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>A retrospective single-center study conducted on all patients in whom treatment with TNFi was initiated in our dermatology clinic in a tertiary university hospital, Riyadh, Saudi Arabia, until September 2018. Data were collected from the hospital electronic patient information system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred and eighteen patients were included. Majority (79.9%) of patients used adalimumab. Psoriasis was the most common indication (90%). Among patients with negative baseline TB screening who had been retested during TNFi therapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 65; 55%), conversion to positive was observed in nine patients (13.8%) with a mean duration of exposure of 39.7 months, whereas among patients with positive TB testing result (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 18), 10 (55.5%) reverted to negative.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study emphasizes the need for prospective large-scale multispecialty studies assessing the significance of TB retesting, which should be considered when designing rescreening protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_201_21","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:08:31Z","timestamp":1649927311000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Conversion Rate of Tuberculosis Screening Tests among Dermatology Patients Treated with Tumor Necrosis Factor Inhibitors"],"prefix":"10.4103","volume":"67","author":[{"given":"Sarah F","family":"Alsukait","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa B","family":"Alsaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadah F","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad M","family":"Alsaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend M","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240829","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","article-title":"Risk assessment of tuberculosis in immunocompromised patients. A TBNET study","volume":"190","author":"Sester","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-1-20240829","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2008.05.033","article-title":"Tuberculosis in the age of biologic therapy","volume":"59","author":"Hernandez","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R3-1-20240829","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/thx.2009.126771","article-title":"Systematic review of interferon-gamma release assays in tuberculosis: Focus on likelihood ratios","volume":"65","author":"Chang","year":"2010","journal-title":"Thorax"},{"key":"R4-1-20240829","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"Hatzara","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-1-20240829","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R6-1-20240829","first-page":"1","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R7-1-20240829","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.dsi.2014.12.005","article-title":"Serial QuantiFERON-TB gold in-tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy","volume":"33","author":"Cheng","year":"2015","journal-title":"Dermatologica Sinica"},{"key":"R8-1-20240829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2018.03.025","article-title":"Low conversion rate of QuantiFERON-TB gold screening tests in patients treated with tumor necrosis factor inhibitors: A retrospective cohort study identifying an important practice gap","volume":"79","author":"Chung","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R9-1-20240829","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/bjd.12544","article-title":"Interferon-\u03b3 release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: In vivo and in vitro analysis","volume":"169","author":"Sauzullo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R10-1-20240829","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1468-3083.2011.04220.x","article-title":"Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: A prospective, observational study","volume":"26","author":"Garcovich","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-1-20240829","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R13-1-20240829","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjd.18461","article-title":"Utility of repeat latent tuberculosis testing with the QuantiFERON-TB gold test in patients with psoriasis treated with tumour necrosis factor-a inhibitors at a single U.S. institution","volume":"182","author":"Ya","year":"2019","journal-title":"Br J Dermatol"},{"key":"R14-1-20240829","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: A systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_201_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:40Z","timestamp":1787755900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_201_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_201_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}